Show simple item record

dc.contributor.authorMarcus, MWen_US
dc.contributor.authorDuffy, SWen_US
dc.contributor.authorDevaraj, Aen_US
dc.contributor.authorGreen, BAen_US
dc.contributor.authorOudkerk, Men_US
dc.contributor.authorBaldwin, Den_US
dc.contributor.authorField, Jen_US
dc.date.accessioned2019-06-03T10:55:00Z
dc.date.available2019-02-11en_US
dc.date.issued2019-08en_US
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/57826
dc.description.abstractBACKGROUND: Estimation of the clinical probability of malignancy in patients with pulmonary nodules will facilitate early diagnosis, determine optimum patient management strategies and reduce overall costs. METHODS: Data from the UK Lung Cancer Screening trial were analysed. Multivariable logistic regression models were used to identify independent predictors and to develop a parsimonious model to estimate the probability of lung cancer in lung nodules detected at baseline and at 3-month and 12-month repeat screening. RESULTS: Of 1994 participants who underwent CT scan, 1013 participants had a total of 5063 lung nodules and 52 (2.6%) of the participants developed lung cancer during a median follow-up of 4 years. Covariates that predict lung cancer in our model included female gender, asthma, bronchitis, asbestos exposure, history of cancer, early and late onset of family history of lung cancer, smoking duration, FVC, nodule type (pure ground-glass and part-solid) and volume as measured by semiautomated volumetry. The final model incorporating all predictors had excellent discrimination: area under the receiver operating characteristic curve (AUC 0.885, 95% CI 0.880 to 0.889). Internal validation suggested that the model will discriminate well when applied to new data (optimism-corrected AUC 0.882, 95% CI 0.848 to 0.907). The risk model had a good calibration (goodness-of-fit χ[8] 8.13, p=0.42). CONCLUSIONS: Our model may be used in estimating the probability of lung cancer in nodules detected at baseline and at 3 months and 12 months from baseline, allowing more efficient stratification of follow-up in population-based lung cancer screening programmes. TRIAL REGISTRATION NUMBER: 78513845.en_US
dc.description.sponsorshipNational Institute for Health Research Health Technology Assessment (NIHR HTA) (reference number HTA 09/61/01).en_US
dc.format.extent761 - 767en_US
dc.languageengen_US
dc.language.isoenen_US
dc.relation.ispartofThoraxen_US
dc.subjectCT Screeningen_US
dc.subjectlung canceren_US
dc.subjectrisk prediction modelen_US
dc.subjectsolitary pulmonary nodulesen_US
dc.titleProbability of cancer in lung nodules using sequential volumetric screening up to 12 months: the UKLS trial.en_US
dc.typeArticle
dc.identifier.doi10.1136/thoraxjnl-2018-212263en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/31028232en_US
pubs.issue8en_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume74en_US
dcterms.dateAccepted2019-02-11en_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record